This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform
by Zacks Equity Research
Ligand (LGND) enters into a worldwide license agreement with Glenmark for OmniAb platform.
Dow 30 Stock Roundup: Boeing Q4 Deliveries Up Y/Y, Success for Merck's Keytruda Combo
by Swarup Gupta
The Dow endured a volatile week during which the index hit a fresh record high.
Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?
by Zacks Equity Research
Merck's (MRK) Keytruda rapidly grows as its key top-line driver. The Keytruda development program shows significant advancement in 2017.
Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference
by Arpita Dutt
Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.
Parkinson's Disease Space Again Under Spotlight This Week
by Zacks Equity Research
Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.
Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference
by Arpita Dutt
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.
5 ETFs to Bet on 2018 Dogs of the Dow
by Sweta Killa
We have highlighted five ETFs with heavy exposure to the Dogs of the Dow that look exciting for 2018.
Merck's Keytruda Combo Gets Breakthrough Therapy Status
by Zacks Equity Research
Merck's (MRK) Keytruda in combination with Eisai's Lenvima gets breakthrough therapy designation from the FDA as a potential treatment for advanced kidney cancer.
Merck's (MRK) Keytruda Succeeds in High-Risk Melanoma Study
by Zacks Equity Research
Merck (MRK) announced that a phase III study evaluating Keytruda as monotherapy for the treatment of high-risk melanoma met the primary endpoint.
Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.
Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs
by Zacks Equity Research
Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.
Alzheimer's takes Another Hit as Pfizer Ends Research in this Area
by Arpita Dutt
With pharma major, Pfizer (PFE), announcing its intention to drop plans to develop treatments for Alzheimer's and certain other disease areas, here is a look at what is going on in this corner of the market.
Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.
Key Biosimilar Approvals in 2017: Progress Report
by Zacks Equity Research
The biosimilar space was much in focus as the FDA approved a few biosimilars for key blockbuster drugs. We expect investor focus on the same in 2018 as well.
Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals
by Arpita Dutt
In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.
Pfizer (PFE) Collaborates With Sangamo for Gene Therapy
by Zacks Equity Research
Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.
Achaogen's NDA for Plazomicin Gets Priority Review From FDA
by Zacks Equity Research
Achaogen's (AKAO) NDA for its urinary tract infections candidate, plazomicin, gets FDA's priority review.
Protalix (PLX) Fabry Disease Candidate Gets Orphan Status
by Zacks Equity Research
Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.
Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?
by Zacks Equity Research
Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.
5 of the Best-Performing Biotech Stocks of 2017
by Arpita Dutt
With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).
Why is Corcept's Stock Up More Than 150% So Far This Year?
by Zacks Equity Research
We take a look at the factors that drove the phenomenal growth in share price of Corcept (CORT) in 2017.
Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies
by Zacks Equity Research
Merck's (MRK) three diabetes drugs get FDA approval as adjunct treatment to diet and exercise to improve glycemic control in patients with diabetes mellitus.
Dow 30 Stock Roundup: Nike Beats, Pfizer Hikes Dividend
by Swarup Gupta
The Dow traversed a choppy week even as the much vaunted tax legislation finally gained legislative approval
Biogen's Alzheimer's Drug Misses Goal in Interim Analysis
by Zacks Equity Research
Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum